Abstract
This retrospective series explores temozolomide monotherapy in elderly patients with primary CNS lymphoma (PCNSL) and severe comorbidities. In 17 patients (62-90 years old), the complete response rate was 47%, median progression-free survival was 5 months, and median overall survival was 21 months. Five of 17 patients (29.4%) had prolonged responses for at least 12 months and survived for more than 24 months. Three of these patients had a methylated O(6)-methylguanine-DNA methyltransferase (MGMT) promoter, while the MGMT status was not assessable in the remaining two patients. Temozolomide monotherapy appears to be effective in a subgroup of elderly PCNSL patients and deserves further evaluation.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents, Alkylating / therapeutic use*
-
Central Nervous System Neoplasms / drug therapy*
-
Central Nervous System Neoplasms / genetics*
-
Central Nervous System Neoplasms / mortality
-
DNA Methylation / drug effects
-
DNA Modification Methylases / metabolism*
-
DNA Repair Enzymes / metabolism*
-
Dacarbazine / analogs & derivatives*
-
Dacarbazine / therapeutic use
-
Disease-Free Survival
-
Female
-
Geriatrics
-
Humans
-
Lymphoma / drug therapy*
-
Lymphoma / genetics
-
Lymphoma / metabolism
-
Male
-
Middle Aged
-
Promoter Regions, Genetic / drug effects
-
Retrospective Studies
-
Survival Analysis
-
Temozolomide
-
Tumor Suppressor Proteins / metabolism*
Substances
-
Antineoplastic Agents, Alkylating
-
Tumor Suppressor Proteins
-
Dacarbazine
-
DNA Modification Methylases
-
MGMT protein, human
-
DNA Repair Enzymes
-
Temozolomide